GENinCode (LSE:GENI) reported preliminary real-world data from a primary care pilot in Catalonia evaluating its CARDIO inCode-Score polygenic risk test for coronary artery disease.

The study involved 584 adults classified as being at moderate cardiovascular risk. According to the preliminary findings, incorporating genetic information changed the overall risk classification in 42.6% of participants.

GENinCode said the data also showed reductions in estimated cardiovascular risk, LDL cholesterol levels and smoking rates over a follow-up period of approximately eight months.

Study evaluates genetic risk alongside conventional assessments

CARDIO inCode-Score is designed to assess an individual’s genetic susceptibility to coronary artery disease and integrate that information with conventional cardiovascular risk assessments.

The pilot examined whether adding polygenic risk information could provide further differentiation among patients initially classified as having moderate risk.

According to the company, the results indicate that genetic risk information could be used to identify patients who may require more intensive preventive treatment while also identifying lower-risk individuals for whom treatment could potentially be reduced.

Findings presented at European Society of Cardiology congress

The preliminary findings were presented at the European Society of Cardiology congress.

GENinCode said the results are also aligned with recent changes to U.S. guidelines concerning cardiovascular risk assessment.

The company believes the use of a genetic test performed once during a patient’s lifetime could contribute to preventive cardiology by providing additional information for treatment decisions.

GENinCode also said broader adoption of polygenic risk scoring could have implications for cost-effectiveness and the allocation of healthcare resources, although the source material does not provide data quantifying these potential effects.

GENinCode focuses on predictive genetic testing

GENinCode Plc is a predictive genetics company developing tests focused on cardiovascular disease prevention and ovarian cancer risk assessment.

Its products include CARDIO inCode-Score, a polygenic risk score designed to assess genetic susceptibility to coronary artery disease.

The company is seeking to integrate genetic information with established cardiovascular risk assessments for use in clinical practice and primary prevention.